Neuroendocrine Tumor Drug Industry Research Report 2025
Description
Summary
According to APO Research, the global Neuroendocrine Tumor Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Neuroendocrine Tumor Drug include Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Midatech Pharma Plc ., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Tumor Drug.
The report will help the Neuroendocrine Tumor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Neuroendocrine Tumor Drug market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuroendocrine Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Neuroendocrine Tumor Drug Segment by Company
Exelixis, Inc.
Foresee Pharmaceuticals, LLC
Hutchison MediPharma Limited
Intezyne, Inc
INVENT Pharmaceuticals, Inc.
Ipsen S.A.
Karyopharm Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
Midatech Pharma Plc .
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Northwest Biotherapeutics, Inc.
OctreoPharm Sciences GmbH
OXiGENE, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Novartis AG
Eisai
Neuroendocrine Tumor Drug Segment by Type
mTOR Protein Inhibitors
Tyrosine Kinase 3 Inhibitors
Growth Hormone Releasing Factor Antagonists
Somatostatin Receptor Agonists
Somatostatin Receptor Antagonists
Others
Neuroendocrine Tumor Drug Segment by Application
Hospital
Clinic
Others
Neuroendocrine Tumor Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neuroendocrine Tumor Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neuroendocrine Tumor Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neuroendocrine Tumor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Neuroendocrine Tumor Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Neuroendocrine Tumor Drug include Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Midatech Pharma Plc ., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Tumor Drug.
The report will help the Neuroendocrine Tumor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Neuroendocrine Tumor Drug market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuroendocrine Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Neuroendocrine Tumor Drug Segment by Company
Exelixis, Inc.
Foresee Pharmaceuticals, LLC
Hutchison MediPharma Limited
Intezyne, Inc
INVENT Pharmaceuticals, Inc.
Ipsen S.A.
Karyopharm Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
Midatech Pharma Plc .
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Northwest Biotherapeutics, Inc.
OctreoPharm Sciences GmbH
OXiGENE, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Novartis AG
Eisai
Neuroendocrine Tumor Drug Segment by Type
mTOR Protein Inhibitors
Tyrosine Kinase 3 Inhibitors
Growth Hormone Releasing Factor Antagonists
Somatostatin Receptor Agonists
Somatostatin Receptor Antagonists
Others
Neuroendocrine Tumor Drug Segment by Application
Hospital
Clinic
Others
Neuroendocrine Tumor Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neuroendocrine Tumor Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neuroendocrine Tumor Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neuroendocrine Tumor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
131 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neuroendocrine Tumor Drug Market Size (2020-2031)
- 2.2.2 Global Neuroendocrine Tumor Drug Sales (2020-2031)
- 2.2.3 Global Neuroendocrine Tumor Drug Market Average Price (2020-2031)
- 2.3 Neuroendocrine Tumor Drug by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 mTOR Protein Inhibitors
- 2.3.3 Tyrosine Kinase 3 Inhibitors
- 2.3.4 Growth Hormone Releasing Factor Antagonists
- 2.3.5 Somatostatin Receptor Agonists
- 2.3.6 Somatostatin Receptor Antagonists
- 2.3.7 Others
- 2.4 Neuroendocrine Tumor Drug by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neuroendocrine Tumor Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Neuroendocrine Tumor Drug Sales (W Units) of Manufacturers (2020-2025)
- 3.3 Global Neuroendocrine Tumor Drug Revenue of Manufacturers (2020-2025)
- 3.4 Global Neuroendocrine Tumor Drug Average Price by Manufacturers (2020-2025)
- 3.5 Global Neuroendocrine Tumor Drug Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Neuroendocrine Tumor Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neuroendocrine Tumor Drug, Product Type & Application
- 3.8 Global Manufacturers of Neuroendocrine Tumor Drug, Established Date
- 3.9 Global Neuroendocrine Tumor Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Exelixis, Inc.
- 4.1.1 Exelixis, Inc. Company Information
- 4.1.2 Exelixis, Inc. Business Overview
- 4.1.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.1.5 Exelixis, Inc. Recent Developments
- 4.2 Foresee Pharmaceuticals, LLC
- 4.2.1 Foresee Pharmaceuticals, LLC Company Information
- 4.2.2 Foresee Pharmaceuticals, LLC Business Overview
- 4.2.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio
- 4.2.5 Foresee Pharmaceuticals, LLC Recent Developments
- 4.3 Hutchison MediPharma Limited
- 4.3.1 Hutchison MediPharma Limited Company Information
- 4.3.2 Hutchison MediPharma Limited Business Overview
- 4.3.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio
- 4.3.5 Hutchison MediPharma Limited Recent Developments
- 4.4 Intezyne, Inc
- 4.4.1 Intezyne, Inc Company Information
- 4.4.2 Intezyne, Inc Business Overview
- 4.4.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio
- 4.4.5 Intezyne, Inc Recent Developments
- 4.5 INVENT Pharmaceuticals, Inc.
- 4.5.1 INVENT Pharmaceuticals, Inc. Company Information
- 4.5.2 INVENT Pharmaceuticals, Inc. Business Overview
- 4.5.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.5.5 INVENT Pharmaceuticals, Inc. Recent Developments
- 4.6 Ipsen S.A.
- 4.6.1 Ipsen S.A. Company Information
- 4.6.2 Ipsen S.A. Business Overview
- 4.6.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio
- 4.6.5 Ipsen S.A. Recent Developments
- 4.7 Karyopharm Therapeutics, Inc.
- 4.7.1 Karyopharm Therapeutics, Inc. Company Information
- 4.7.2 Karyopharm Therapeutics, Inc. Business Overview
- 4.7.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.7.5 Karyopharm Therapeutics, Inc. Recent Developments
- 4.8 Lexicon Pharmaceuticals, Inc.
- 4.8.1 Lexicon Pharmaceuticals, Inc. Company Information
- 4.8.2 Lexicon Pharmaceuticals, Inc. Business Overview
- 4.8.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.8.5 Lexicon Pharmaceuticals, Inc. Recent Developments
- 4.9 Midatech Pharma Plc .
- 4.9.1 Midatech Pharma Plc . Company Information
- 4.9.2 Midatech Pharma Plc . Business Overview
- 4.9.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio
- 4.9.5 Midatech Pharma Plc . Recent Developments
- 4.10 Millennium Pharmaceuticals, Inc.
- 4.10.1 Millennium Pharmaceuticals, Inc. Company Information
- 4.10.2 Millennium Pharmaceuticals, Inc. Business Overview
- 4.10.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.10.5 Millennium Pharmaceuticals, Inc. Recent Developments
- 4.11 MolMed S.p.A.
- 4.11.1 MolMed S.p.A. Company Information
- 4.11.2 MolMed S.p.A. Business Overview
- 4.11.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio
- 4.11.5 MolMed S.p.A. Recent Developments
- 4.12 Northwest Biotherapeutics, Inc.
- 4.12.1 Northwest Biotherapeutics, Inc. Company Information
- 4.12.2 Northwest Biotherapeutics, Inc. Business Overview
- 4.12.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.12.5 Northwest Biotherapeutics, Inc. Recent Developments
- 4.13 OctreoPharm Sciences GmbH
- 4.13.1 OctreoPharm Sciences GmbH Company Information
- 4.13.2 OctreoPharm Sciences GmbH Business Overview
- 4.13.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio
- 4.13.5 OctreoPharm Sciences GmbH Recent Developments
- 4.14 OXiGENE, Inc.
- 4.14.1 OXiGENE, Inc. Company Information
- 4.14.2 OXiGENE, Inc. Business Overview
- 4.14.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.14.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.14.5 OXiGENE, Inc. Recent Developments
- 4.15 Jiangsu Hengrui Medicine Co., Ltd.
- 4.15.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
- 4.15.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
- 4.15.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.15.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio
- 4.15.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
- 4.16 Novartis AG
- 4.16.1 Novartis AG Company Information
- 4.16.2 Novartis AG Business Overview
- 4.16.3 Novartis AG Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.16.4 Novartis AG Neuroendocrine Tumor Drug Product Portfolio
- 4.16.5 Novartis AG Recent Developments
- 4.17 Eisai
- 4.17.1 Eisai Company Information
- 4.17.2 Eisai Business Overview
- 4.17.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.17.4 Eisai Neuroendocrine Tumor Drug Product Portfolio
- 4.17.5 Eisai Recent Developments
- 5 Global Neuroendocrine Tumor Drug Market Scenario by Region
- 5.1 Global Neuroendocrine Tumor Drug Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Neuroendocrine Tumor Drug Sales by Region: 2020-2031
- 5.2.1 Global Neuroendocrine Tumor Drug Sales by Region: 2020-2025
- 5.2.2 Global Neuroendocrine Tumor Drug Sales by Region: 2026-2031
- 5.3 Global Neuroendocrine Tumor Drug Revenue by Region: 2020-2031
- 5.3.1 Global Neuroendocrine Tumor Drug Revenue by Region: 2020-2025
- 5.3.2 Global Neuroendocrine Tumor Drug Revenue by Region: 2026-2031
- 5.4 North America Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.4.1 North America Neuroendocrine Tumor Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Neuroendocrine Tumor Drug Sales by Country (2020-2031)
- 5.4.3 North America Neuroendocrine Tumor Drug Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.5.1 Europe Neuroendocrine Tumor Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Neuroendocrine Tumor Drug Sales by Country (2020-2031)
- 5.5.3 Europe Neuroendocrine Tumor Drug Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neuroendocrine Tumor Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Neuroendocrine Tumor Drug Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Neuroendocrine Tumor Drug Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.7.1 South America Neuroendocrine Tumor Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Neuroendocrine Tumor Drug Sales by Country (2020-2031)
- 5.7.3 South America Neuroendocrine Tumor Drug Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Neuroendocrine Tumor Drug Sales by Type (2020-2031)
- 6.1.1 Global Neuroendocrine Tumor Drug Sales by Type (2020-2031) & (W Units)
- 6.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2031)
- 6.2 Global Neuroendocrine Tumor Drug Revenue by Type (2020-2031)
- 6.2.1 Global Neuroendocrine Tumor Drug Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2020-2031)
- 6.3 Global Neuroendocrine Tumor Drug Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Neuroendocrine Tumor Drug Sales by Application (2020-2031)
- 7.1.1 Global Neuroendocrine Tumor Drug Sales by Application (2020-2031) & (W Units)
- 7.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2031)
- 7.2 Global Neuroendocrine Tumor Drug Revenue by Application (2020-2031)
- 7.2.1 Global Neuroendocrine Tumor Drug Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2020-2031)
- 7.3 Global Neuroendocrine Tumor Drug Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neuroendocrine Tumor Drug Value Chain Analysis
- 8.1.1 Neuroendocrine Tumor Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neuroendocrine Tumor Drug Production Mode & Process
- 8.2 Neuroendocrine Tumor Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neuroendocrine Tumor Drug Distributors
- 8.2.3 Neuroendocrine Tumor Drug Customers
- 9 Global Neuroendocrine Tumor Drug Analyzing Market Dynamics
- 9.1 Neuroendocrine Tumor Drug Industry Trends
- 9.2 Neuroendocrine Tumor Drug Industry Drivers
- 9.3 Neuroendocrine Tumor Drug Industry Opportunities and Challenges
- 9.4 Neuroendocrine Tumor Drug Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Neuroendocrine Tumor Drug Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Neuroendocrine Tumor Drug Sales (W Units) of Manufacturers (2020-2025)
- Table 7. Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Neuroendocrine Tumor Drug Revenue of Manufacturers (2020-2025)
- Table 9. Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Neuroendocrine Tumor Drug Average Price (US$/Unit) of Manufacturers (2020-2025)
- Table 11. Global Neuroendocrine Tumor Drug Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Neuroendocrine Tumor Drug, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Neuroendocrine Tumor Drug, Product Type & Application
- Table 14. Global Neuroendocrine Tumor Drug Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Neuroendocrine Tumor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Exelixis, Inc. Company Information
- Table 19. Exelixis, Inc. Business Overview
- Table 20. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 21. Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio
- Table 22. Exelixis, Inc. Recent Developments
- Table 23. Foresee Pharmaceuticals, LLC Company Information
- Table 24. Foresee Pharmaceuticals, LLC Business Overview
- Table 25. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 26. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio
- Table 27. Foresee Pharmaceuticals, LLC Recent Developments
- Table 28. Hutchison MediPharma Limited Company Information
- Table 29. Hutchison MediPharma Limited Business Overview
- Table 30. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 31. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio
- Table 32. Hutchison MediPharma Limited Recent Developments
- Table 33. Intezyne, Inc Company Information
- Table 34. Intezyne, Inc Business Overview
- Table 35. Intezyne, Inc Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 36. Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio
- Table 37. Intezyne, Inc Recent Developments
- Table 38. INVENT Pharmaceuticals, Inc. Company Information
- Table 39. INVENT Pharmaceuticals, Inc. Business Overview
- Table 40. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 41. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- Table 42. INVENT Pharmaceuticals, Inc. Recent Developments
- Table 43. Ipsen S.A. Company Information
- Table 44. Ipsen S.A. Business Overview
- Table 45. Ipsen S.A. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 46. Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio
- Table 47. Ipsen S.A. Recent Developments
- Table 48. Karyopharm Therapeutics, Inc. Company Information
- Table 49. Karyopharm Therapeutics, Inc. Business Overview
- Table 50. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 51. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
- Table 52. Karyopharm Therapeutics, Inc. Recent Developments
- Table 53. Lexicon Pharmaceuticals, Inc. Company Information
- Table 54. Lexicon Pharmaceuticals, Inc. Business Overview
- Table 55. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 56. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- Table 57. Lexicon Pharmaceuticals, Inc. Recent Developments
- Table 58. Midatech Pharma Plc . Company Information
- Table 59. Midatech Pharma Plc . Business Overview
- Table 60. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 61. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio
- Table 62. Midatech Pharma Plc . Recent Developments
- Table 63. Millennium Pharmaceuticals, Inc. Company Information
- Table 64. Millennium Pharmaceuticals, Inc. Business Overview
- Table 65. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 66. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- Table 67. Millennium Pharmaceuticals, Inc. Recent Developments
- Table 68. MolMed S.p.A. Company Information
- Table 69. MolMed S.p.A. Business Overview
- Table 70. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 71. MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio
- Table 72. MolMed S.p.A. Recent Developments
- Table 73. Northwest Biotherapeutics, Inc. Company Information
- Table 74. Northwest Biotherapeutics, Inc. Business Overview
- Table 75. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 76. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
- Table 77. Northwest Biotherapeutics, Inc. Recent Developments
- Table 78. OctreoPharm Sciences GmbH Company Information
- Table 79. OctreoPharm Sciences GmbH Business Overview
- Table 80. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 81. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio
- Table 82. OctreoPharm Sciences GmbH Recent Developments
- Table 83. OXiGENE, Inc. Company Information
- Table 84. OXiGENE, Inc. Business Overview
- Table 85. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 86. OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio
- Table 87. OXiGENE, Inc. Recent Developments
- Table 88. Jiangsu Hengrui Medicine Co., Ltd. Company Information
- Table 89. Jiangsu Hengrui Medicine Co., Ltd. Business Overview
- Table 90. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 91. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio
- Table 92. Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
- Table 93. Novartis AG Company Information
- Table 94. Novartis AG Business Overview
- Table 95. Novartis AG Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 96. Novartis AG Neuroendocrine Tumor Drug Product Portfolio
- Table 97. Novartis AG Recent Developments
- Table 98. Eisai Company Information
- Table 99. Eisai Business Overview
- Table 100. Eisai Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 101. Eisai Neuroendocrine Tumor Drug Product Portfolio
- Table 102. Eisai Recent Developments
- Table 103. Global Neuroendocrine Tumor Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 104. Global Neuroendocrine Tumor Drug Sales by Region (2020-2025) & (W Units)
- Table 105. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2020-2025)
- Table 106. Global Neuroendocrine Tumor Drug Sales by Region (2026-2031) & (W Units)
- Table 107. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2026-2031)
- Table 108. Global Neuroendocrine Tumor Drug Revenue by Region (2020-2025) & (US$ Million)
- Table 109. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2020-2025)
- Table 110. Global Neuroendocrine Tumor Drug Revenue by Region (2026-2031) & (US$ Million)
- Table 111. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2026-2031)
- Table 112. North America Neuroendocrine Tumor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 113. North America Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (W Units)
- Table 114. North America Neuroendocrine Tumor Drug Sales by Country (2026-2031) & (W Units)
- Table 115. North America Neuroendocrine Tumor Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 116. North America Neuroendocrine Tumor Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 117. Europe Neuroendocrine Tumor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 118. Europe Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (W Units)
- Table 119. Europe Neuroendocrine Tumor Drug Sales by Country (2026-2031) & (W Units)
- Table 120. Europe Neuroendocrine Tumor Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 121. Europe Neuroendocrine Tumor Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 122. Asia Pacific Neuroendocrine Tumor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 123. Asia Pacific Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (W Units)
- Table 124. Asia Pacific Neuroendocrine Tumor Drug Sales by Country (2026-2031) & (W Units)
- Table 125. Asia Pacific Neuroendocrine Tumor Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 126. Asia Pacific Neuroendocrine Tumor Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 127. South America Neuroendocrine Tumor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 128. South America Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (W Units)
- Table 129. South America Neuroendocrine Tumor Drug Sales by Country (2026-2031) & (W Units)
- Table 130. South America Neuroendocrine Tumor Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 131. South America Neuroendocrine Tumor Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 132. Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 133. Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (W Units)
- Table 134. Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2026-2031) & (W Units)
- Table 135. Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 136. Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 137. Global Neuroendocrine Tumor Drug Sales by Type (2020-2025) & (W Units)
- Table 138. Global Neuroendocrine Tumor Drug Sales by Type (2026-2031) & (W Units)
- Table 139. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
- Table 140. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2026-2031)
- Table 141. Global Neuroendocrine Tumor Drug Revenue by Type (2020-2025) & (US$ Million)
- Table 142. Global Neuroendocrine Tumor Drug Revenue by Type (2026-2031) & (US$ Million)
- Table 143. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2020-2025)
- Table 144. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2026-2031)
- Table 145. Global Neuroendocrine Tumor Drug Price by Type (2020-2025) & (US$/Unit)
- Table 146. Global Neuroendocrine Tumor Drug Price by Type (2026-2031) & (US$/Unit)
- Table 147. Global Neuroendocrine Tumor Drug Sales by Application (2020-2025) & (W Units)
- Table 148. Global Neuroendocrine Tumor Drug Sales by Application (2026-2031) & (W Units)
- Table 149. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2025)
- Table 150. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2026-2031)
- Table 151. Global Neuroendocrine Tumor Drug Revenue by Application (2020-2025) & (US$ Million)
- Table 152. Global Neuroendocrine Tumor Drug Revenue by Application (2026-2031) & (US$ Million)
- Table 153. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2020-2025)
- Table 154. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2026-2031)
- Table 155. Global Neuroendocrine Tumor Drug Price by Application (2020-2025) & (US$/Unit)
- Table 156. Global Neuroendocrine Tumor Drug Price by Application (2026-2031) & (US$/Unit)
- Table 157. Key Raw Materials
- Table 158. Raw Materials Key Suppliers
- Table 159. Neuroendocrine Tumor Drug Distributors List
- Table 160. Neuroendocrine Tumor Drug Customers List
- Table 161. Neuroendocrine Tumor Drug Industry Trends
- Table 162. Neuroendocrine Tumor Drug Industry Drivers
- Table 163. Neuroendocrine Tumor Drug Industry Restraints
- Table 164. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Neuroendocrine Tumor Drug Product Image
- Figure 5. Global Neuroendocrine Tumor Drug Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Neuroendocrine Tumor Drug Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Neuroendocrine Tumor Drug Sales (2020-2031) & (W Units)
- Figure 8. Global Neuroendocrine Tumor Drug Average Price (US$/Unit) & (2020-2031)
- Figure 9. mTOR Protein Inhibitors Product Image
- Figure 10. Tyrosine Kinase 3 Inhibitors Product Image
- Figure 11. Growth Hormone Releasing Factor Antagonists Product Image
- Figure 12. Somatostatin Receptor Agonists Product Image
- Figure 13. Somatostatin Receptor Antagonists Product Image
- Figure 14. Others Product Image
- Figure 15. Hospital Product Image
- Figure 16. Clinic Product Image
- Figure 17. Others Product Image
- Figure 18. Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers in 2024
- Figure 19. Global Manufacturers of Neuroendocrine Tumor Drug, Manufacturing Sites & Headquarters
- Figure 20. Global Top 5 and 10 Neuroendocrine Tumor Drug Players Market Share by Revenue in 2024
- Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 22. Global Neuroendocrine Tumor Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 23. Global Neuroendocrine Tumor Drug Sales by Region in 2024
- Figure 24. Global Neuroendocrine Tumor Drug Revenue by Region in 2024
- Figure 25. North America Neuroendocrine Tumor Drug Market Size by Country in 2024
- Figure 26. North America Neuroendocrine Tumor Drug Sales Market Share by Country (2020-2031)
- Figure 27. North America Neuroendocrine Tumor Drug Revenue Market Share by Country (2020-2031)
- Figure 28. United States Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 29. Canada Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 30. Europe Neuroendocrine Tumor Drug Market Size by Country in 2024
- Figure 31. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2020-2031)
- Figure 32. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country (2020-2031)
- Figure 33. Germany Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. France Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. U.K. Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. Italy Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Netherlands Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Nordic Countries Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. Asia Pacific Neuroendocrine Tumor Drug Market Size by Country in 2024
- Figure 40. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Country (2020-2031)
- Figure 41. Asia Pacific Neuroendocrine Tumor Drug Revenue Market Share by Country (2020-2031)
- Figure 42. China Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 43. Japan Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. South Korea Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. India Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. Australia Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. China Taiwan Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. Southeast Asia Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. Southeast Asia Neuroendocrine Tumor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. South America Neuroendocrine Tumor Drug Market Size by Country in 2024
- Figure 51. South America Neuroendocrine Tumor Drug Sales Market Share by Country (2020-2031)
- Figure 52. South America Neuroendocrine Tumor Drug Revenue Market Share by Country (2020-2031)
- Figure 53. Mexico Neuroendocrine Tu
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
